Role of N-Terminal Pro-brain Natriuretic Peptide in the Early Diagnosis of Neonatal Sepsis

Abstract

Objective Sepsis is one of the most significant contributors to mortality and morbidity in the neonatal population. The need to find specific biomarkers that provide meaningful information about the diagnosis of sepsis is still ongoing. This study aimed to investigate the utility of N-terminal pro-brain natriuretic peptide (NT-proBNP) as a diagnostic biomarker in newborn infants with late-onset sepsis.

Methods A prospective, observational study was conducted in the neonatal intensive care unit between July 2016 and January 2017. The patients suspected of having late-onset sepsis and meeting the selection criteria were included in the study, and serial measurements of white blood cell count, serum C-reactive protein (CRP), plasma interleukin (IL) 6, and whole blood NT-proBNP levels were performed.

Results The study included 87 patients diagnosed with sepsis and 35 control patients. The median NT-proBNP levels were higher in septic patients (58 [22–169] vs. 14 [7–21]; p < 0.001), showing a significant correlation with CRP and IL-6 levels (r = 0.327, p < 0.01 and r = 0.216, p < 0.05, respectively). The optimal diagnostic cutoff value for differentiating sepsis was 27.5 pg/mL. Predictive parameters of NT-proBNP, such as sensitivity (72%) and specificity (86%), were comparable to those of CRP and IL-6 for the early diagnosis of sepsis in neonates.

Conclusion Plasma NT-proBNP levels were higher in septic neonates, and the predictive values were comparable to those of CRP and IL-6. However, these values were not high enough to make it a reliable diagnostic biomarker for identifying neonates in the early stages of sepsis.

Keywords

preterm - sepsis - proBNP

• References

• 1 Bizzarro MJ, Raskind C, Baltimore RS, Gallagher PG. Seventy-five years of neonatal sepsis at Yale: 1928-2003. Pediatrics 2005; 116 (03) 595-602
• 2 Stoll BJ, Hansen NI, Adams-Chapman I. , et al; National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004; 292 (19) 2357-2365
• 3 Camacho-Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin North Am 2013; 60 (02) 367-389
• 4 Gilfillan M, Bhandari V. Biomarkers for the diagnosis of neonatal sepsis and necrotizing enterocolitis: clinical practice guidelines. Early Hum Dev 2017; 105: 25-33
• 5 Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50 (25) 2357-2368
• 6 Ogawa T, de Bold AJ. Brain natriuretic peptide production and secretion in inflammation. J Transplant 2012; 2012: 962347
• 7 Piechota M, Barylski M, Hannam S, Mikhailidis DP, Rysz J, Banach M. Natriuretic peptides in septic patients. Curr Med Chem 2009; 16 (30) 4020-4031
• 8 Wang F, Wu Y, Tang L. , et al. Brain natriuretic peptide for prediction of mortality in patients with sepsis: a systematic review and meta-analysis. Crit Care 2012; 16 (03) R74
• 9 Lin CW, Tang W, Wen F, Chen JJ, Zeng XL, Chen ZG. Diagnostic accuracy of NT-ProBNP for heart failure with sepsis in patients younger than 18 years. PLoS One 2016; 11 (01) e0147930
• 10 Samransamruajkit R, Uppala R, Pongsanon K, Deelodejanawong J, Sritippayawan S, Prapphal N. Clinical outcomes after utilizing surviving sepsis campaign in children with septic shock and prognostic value of initial plasma NT-proBNP. Indian J Crit Care Med 2014; 18 (02) 70-76
• 11 Wu JR, Chen IC, Dai ZK, Hung JF, Hsu JH. Early elevated B-type natriuretic peptide levels are associated with cardiac dysfunction and poor clinical outcome in pediatric septic patients. Acta Cardiol Sin 2015; 31 (06) 485-493
• 12 Kulkarni M, Gokulakrishnan G, Price J, Fernandes CJ, Leeflang M, Pammi M. Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review. Pediatrics 2015; 135 (02) e510-e525
• 13 El-Khuffash A, Molloy E. The use of N-terminal-pro-BNP in preterm infants. Int J Pediatr 2009; 2009: 175216
• 14 Nir A, Lindinger A, Rauh M. , et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009; 30 (01) 3-8
• 15 Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36 (05) 309-332
• 16 İpek MS, Aktar F, Okur N, Celik M, Ozbek E. Colistin use in critically ill neonates: a case-control study. Pediatr Neonatol 2017; 58 (06) 490-496
• 17 Celik IH, Demirel FG, Uras N. , et al. What are the cut-off levels for IL-6 and CRP in neonatal sepsis?. J Clin Lab Anal 2010; 24 (06) 407-412
• 18 Rudiger A, Gasser S, Fischler M, Hornemann T, von Eckardstein A, Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006; 34 (08) 2140-2144
• 19 Zhang XH, Dong Y, Chen YD, Zhou P, Wang JD, Wen FQ. Serum N-terminal pro-brain natriuretic peptide level is a significant prognostic factor in patients with severe sepsis among Southwest Chinese population. Eur Rev Med Pharmacol Sci 2013; 17 (04) 517-521
• 20 Tomaru Ki K, Arai M, Yokoyama T. , et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002; 34 (06) 649-659
• 21 Maeder M, Fehr T, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006; 129 (05) 1349-1366
• 22 Valette X, Lemoine S, Allouche S, Gérard JL, Hanouz JL. Effect of lipopolysaccharide, cytokines, and catecholamines on brain natriuretic peptide release from human myocardium. Acta Anaesthesiol Scand 2012; 56 (07) 860-865
• 23 Vila G, Resl M, Stelzeneder D. , et al. Plasma NT-proBNP increases in response to LPS administration in healthy men. J Appl Physiol (1985) 2008; 105 (06) 1741-1745
• 24 Li X, Peng H, Wu J, Xu Y. Brain natriuretic peptide-regulated expression of inflammatory cytokines in lipopolysaccharide (LPS)-activated macrophages via NF-κB and mitogen activated protein kinase (MAPK) pathways. Med Sci Monit 2018; 24: 3119-3126
• 25 Chiurchiù V, Izzi V, D'Aquilio F, Carotenuto F, Di Nardo P, Baldini PM. Brain natriuretic peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept 2008; 148 (1-3): 26-32
• 26 Lv X, Wang H. Pathophysiology of sepsis-induced myocardial dysfunction. Mil Med Res 2016; 3: 30
• 27 Charpentier J, Luyt CE, Fulla Y. , et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32 (03) 660-665
• 28 Shor R, Rozenman Y, Bolshinsky A. , et al. BNP in septic patients without systolic myocardial dysfunction. Eur J Intern Med 2006; 17 (08) 536-540
• 29 Hur M, Kim H, Lee S. , et al. Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis. BMC Infect Dis 2014; 14: 224
• 30 Goei D, Schouten O, Boersma E. , et al. Influence of renal function on the usefulness of N-terminal pro-B-type natriuretic peptide as a prognostic cardiac risk marker in patients undergoing noncardiac vascular surgery. Am J Cardiol 2008; 101 (01) 122-126